MPR delivers practical, up-to-date drug information to healthcare professionals. Using the expertise gained from 25 years of providing point-of-care drug tools, MPR has now created a drug review course exclusively for See below for a list of each quarter's courses. Click here to visit MPR's website.

Latest Courses

Clinical Review

New-Drug Review from MPR (April 2014)

1.00 Credits

MPR Drug News

Harvoni for HCV Genotype 4, HIV Co-Infection Assessed in New Research

Gilead Sciences announced results from ION-4, a Phase 3 study evaluating Harvoni (ledipasvir 90mg/sofosbuvir 400mg) for the treatment of genotypes 1 or 4 chronic hepatitis C virus (HCV) infection among patients co-infected with HIV.

Combo Therapy for HCV, HIV Co-Infection: New Data on Sustained Virologic Response

Bristol-Myers Squibb Company announced results from ALLY-2, a Phase 3 trial evaluating the use of daclatasvir and sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) co-infected with HIV.

What's Changed in Immunization Recommendations From CDC Advisory Committee

The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has issued new recommendations on immunizations, including influenza, serogroup B meningococcal, and human papillomavirus (HPV) vaccination.

Lenvima Now Available Through Specialty Pharmacies

Lenvima (lenvatinib; Eisai) is now available through two specialty pharmacies, Accredo and Biologics Inc. for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).

IUD Approval Gives Women New Long-Acting Birth Control Option

The Food and Drug Administration (FDA) has approved Liletta (levonorgestrol-releasing intrauterine system; Actavis and Medicines360) for use by women to prevent pregnancy for up to three years.